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Abstract
Introduction: This article presents the results of a single-day census of
radiation therapy (RT) treatment and technology use in Australia. The primary
aim of the study was to ascertain patterns of RT practice and technology in use
across Australia. These data were primarily collated to inform curriculum
development of academic programs, thereby ensuring that training is matched
to workforce patterns of practice. Methods: The study design was a census
method with all 59 RT centres in Australia being invited to provide
quantitative summary data relating to patient case mix and technology use on a
randomly selected but common date. Anonymous and demographic-free data
were analysed using descriptive statistics. Results: Overall data were provided
across all six Australian States by 29 centres of a possible 59, yielding a
response rate of 49% and representing a total of 2743 patients. Findings from
this study indicate the increasing use of emerging intensity-modulated
radiotherapy (IMRT), image fusion and image-guided radiation therapy (IGRT)
technology in Australian RT planning and delivery phases. IMRT in particular
was used for 37% of patients, indicating a high uptake of the technology in
Australia when compared to other published data. The results also highlight the
resource-intensive nature of benign tumour radiotherapy. Conclusions: In the
absence of routine national data collection, the single-day census method offers
a relatively convenient means of measuring and tracking RT resource
utilisation. Wider use of this tool has the potential to not only track trends in
technology implementation but also inform evidence-based guidelines for
referral and resource planning.
Introduction
Regular audits in the literature attempt to track trends in
availability of radiation therapy (RT) technology such as
intensity-modulated radiotherapy (IMRT)1 from a range
of countries.2–4 There is a big difference, however,
between the availability of resources and actual usage
with the resource-hungry nature of commissioning5 in
particular affecting implementation and usage of the
available technology and equipment.6 Mayles’ 2010 UK
study7 remains one of the few to investigate the link
between availability and use of technology and
determined that lack of personnel and funding was a
common inhibitory factor rather than availability of
technology. In the absence of formal national data
collection procedures such as the UK RT dataset,8 there is
a lack of data describing Australian RT patterns. This
national study was built on the findings of a 2012 state-
wide audit9 of practice in Queensland that used a fast
and simple method to collect data concerning RT
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indications and routine technology usage. The primary
aim of the study was to ascertain patterns of RT practice
and technology in use across Australia. These data would
then be used to inform curriculum development of
academic programs, thereby ensuring that training is
matched to workforce patterns of practice. The secondary
aim of the study was to compare the findings with those
of the previous audit and additional published data to
determine trends in practice.
Methods
The study design was a census method as previously
validated.9 All 59 Australian RT centres in operation at
the time of the study were invited to provide quantitative
summary data relating to patient case mix and technology
use on a randomly selected but common date (Thursday
5th December 2013). Anonymous demographic-free data
were harvested using a Microsoft Excel© spreadsheet
proforma adapted and validated from the previous study9
and was analysed using descriptive statistics.
Modifications to the original format included separate
consideration of left and right breast, radical and
palliative classification and slightly amended tumour
categories as informed by the previous iteration.
Clinical centres were approached by local clinical and
academic RT educators who sought permission of centre
managers and data collection was coordinated by State
educator representatives. As with the previous study,
ethical exemption was provided by the coordinating
University Research Ethics Committee due to the
anonymous nature of the data collection and the use of
already existing datasets.
The results were combined to provide summary data
relating to a number of key themes including tumour
case mix and usage of IMRT, image fusion and on-
treatment imaging modalities. Tumour case mix analysis
indicated the relative incidence of the patients on the
chosen day along with the range of techniques used. Data
relating to technology use were classified into two
separate measures. “Indication” data identified the
tumour sites that were most likely to use the technology.
“Usage” data indicated how the technology use was
distributed among different sites. Results from this audit
were directly compared to the previous results from the
Queensland-wide study and published data to determine
trends.
Results
Overall data were provided from centres in all six
Australian States by 29 centres of a possible 59, yielding a
response rate of 49%. A total of 2743 patients were
treated on the chosen date across these centres and
Table 1 presents a summary of the national and state-
wide responses. Radical treatments comprised 81.6% of
the total workload and over 91% of treatments used
megavoltage equipment with only 2.5% of treatments
using kilovoltage therapy. A total of 198 patients (7.2%)
received electron treatment either standalone or
concurrent with megavoltage (Table 1).
Table 2 illustrates the 10 most common tumour sites
treated radically as both an absolute number and as a
percentage of all radial treatments. The Table also
compares this list with results from the previous
Queensland-based audit9 as well as Barton’s 201310
summary of the most common sites indicated for
radiotherapy nationally in Australia. The most common
sites receiving RT were as expected and largely as
indicated in the previous study.9 RT of the breast,
prostate and head and neck together comprised 62% of
the total radical fractions as seen in Table 2. The five
most common tumour sites according to the adopted
categories for this study were breast, prostate, head and
neck, skin and breast with nodes (including additional
axillary or supraclavicular fields). These were the same as
the previous study,9 with mostly similar incidence rates.
The exception was breast which comprised almost 33% of
radical treatments in this iteration but only 18.4% in the
previous.
IMRT-related data are summarised in Table 3 with the
left hand section showing data for fixed angle IMRT and
the right hand showing data for volumetric-modulated
arc therapy (VMAT), including tomotherapy. A total of
1007 (37%) of the treated patients received IMRT and
16% of these received VMAT using dynamic linear
accelerator or tomotherapy technology. The “% of IMRT”
column shows how IMRT is distributed among the
various tumour sites with prostate accounting for over
31% of usage. The” % use per site” values indicate the
percentage of each tumour site patients receiving IMRT;
Table 1. Summary of state-wide data.
State Patients Radical MV E kV Images IMRT Fusion
NSW 733 612 664 35 40 616 412 163
QLD 854 688 768 98 8 671 221 143
SA 338 286 309 17 2 314 75 52
TAS 71 54 67 5 0 70 11 16
VIC 582 473 539 30 18 556 127 119
WA 165 125 152 13 0 148 164 23
Total 2743 2238 2499 198 68 2268 1010 516
NSW, New South Wales; QLD, Queensland; SA, South Australia; TAS,
Tasmania; VIC, Victoria; WA, Western Australia; MV, megavoltage
radiotherapy; E, electrons; kV, kilovoltage radiotherapy; IMRT,
intensity-modulated radiation therapy.
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it can thus be seen that over 71% of prostate patients
receive IMRT. As in the previous study, the most
common sites for IMRT (as a proportion of all IMRT
treatments) were still prostate, breast and head and neck,
although VMAT was not used for breast treatments. It
was interesting to note that IMRT was more commonly
delivered to the right breast (31%) than the left (23.5%),
despite the increased challenge of cardiac toxicity on the
left. This is at odds with published data11 which reported
more frequent use of IMRT for the left breast. Overall,
arc therapies were used for 160 (6%) of all patient cases,
with tomotherapy delivering a little under one-third of
these. Most tomotherapy treatments were delivered to
head and neck cancers with the oropharynx accounting
for 41%. VMAT delivered the remaining arc therapy
treatments, with 62% of being used for prostate, and 17%
for head and neck. Intensity modulation was used in
preference to other RT modalities for prostate and head
and neck, with IMRT or VMAT used in 71% and 65% of
these sites respectively.
Data in Table 4 relate to usage of magnetic resonance
imaging (MRI) and computed tomography (CT) fusion,
where it can be seen that prostate and brain tumours
made by far the most demands on the modality. Overall
9.8% of patients had their RT planned using this form of
imaging. The left hand section presents the percentage of
total MRI fusions for each tumour site while the right
hand columns show the percentage of tumour site
patients receiving MRI fusion. It can be seen that over
68% of benign tumours benefited from MRI fusion;
significantly more than any other tumour site.
Table 5 illustrates the main indications for positron
emission tomography (PET)-CT fusion with lung and
head and neck comprising over 50% of the indications.
The data from this study suggested that 9% of patients
were planned with PET-CT. As indicated in Table 5,
cancers of the lung, head and neck, oesophagus and
rectum were the most common sites for this form of
image fusion, with over 30% of lung cancer patients
benefitting from the technology.
Data were also gathered to highlight usage of
kilovoltage and megavoltage portal imaging as well as
cone-beam CT modalities. Planar imaging modalities are
the most common modalities, comprising over 80% of
Table 2. Top 10 indications for radical radiotherapy.
Current study Barton 201310 Bridge 20109
Site n % Site % Site n %
Breast 732 32.72 Prostate 22.15 Breast 258 26.26
Prostate 426 19.04 Breast 21.94 Prostate 209 21.28
Head and neck 233 10.42 Lung 14.28 Head and neck 71 7.23
Skin 179 8.00 Lymphoma 6.42 Lung 62 6.31
Lung 132 5.90 Rectum 5.18 Skin SCC 58 5.90
Brain 92 4.11 Head and neck 4.97 Rectum 38 3.87
Rectum 89 3.98 Melanoma 4.35 Brain 31 3.16
Uterus 36 1.61 Unknown primary 3.11 Oesophagus 21 2.14
Oesophagus 35 1.56 Brain 2.28 Cervix 19 1.93
Bladder 29 1.30 Pancreas 2.07 Lymphoma 19 1.93
Table 3. Top 10 intensity-modulated radiotherapy (IMRT) indications and usage.
All IMRT Arc IMRT
Site n Percentage of IMRT Percentage use per site Site n Percentage of IMRT
Prostate 313 31.08 71.30 Prostate 74 7.35
Breast 201 19.96 27.16 Head and neck 44 4.37
Head and neck 163 16.19 65.46 Brain 9 0.89
Brain 78 7.75 44.07 Lung 8 0.79
Bone 41 4.07 30.60 Uterus 3 0.30
Skin 41 4.07 20.00 Melanoma 3 0.30
Lung 29 2.88 15.03 Skin 2 0.20
Anus 16 1.59 59.26 Benign tumours 2 0.20
Rectum 16 1.59 15.53 Lymph nodes 2 0.20
Benign Tumours 10 0.99 52.63 Soft-tissue sarcoma 2 0.20
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instances as seen in Table 6. Overall 99% of patients
received imaging; some patients received multiple
imaging modalities but the summary data will not permit
further analysis. All ultrasound images were related to
prostate localisation.
Discussion
Overall the national rate of response to the survey was
49% of centres. Although this was below that reported in
previous studies,1,9 it does provide a reasonable indication
of national practice. Some interesting themes were
extracted from the data and further discussion and
comparison with published findings follows.
Indications for RT
The 2012 study reported slightly higher rates of electron
therapy (10.7%) and lower rates of kilovoltage therapy
(0.5%). Interestingly, the Queensland-only data for this
study reported a 0.9% kilovoltage rate, suggesting a
reduction in this iteration compared to the previous
Queensland-based study. In 2010, the five most
commonly diagnosed cancers in Australia were prostate
(19,821 cases), bowel (14,860), breast (14,308), melanoma
(11,405) and lung (10,296).12 These figures map
consistently with the data from this study as prostate and
breast cancer are commonly treated with RT, although it
must be acknowledged that some of the most common
cancers are not demonstrated. An Australian review of
optimal RT utilisation rates based on evidence-based
treatment guidelines was published in March 2013.10 This
suggested that in Australia, RT (alone or with
chemotherapy or brachytherapy) is the treatment of
choice for 48.3% of notifiable cancers. Table 2 illustrates
the new indicated RT utilisation rate for the 10 most
common site-specific cancers and the national proportion
of new cases of cancer with an indication for
radiotherapy, which compares well to our data. This
study’s data are therefore well validated with the
published findings in terms of the incidence of site-
specific cancers and those treated in the highest 10
categories.
Patterns of IMRT use
There was considerable variability between States in terms
of IMRT use ranging from over 99% of patients in
Western Australia to 15.5% in Tasmania. These extreme
figures, however, are only drawn from single-centre data
so should be interpreted with caution. Most States used
IMRT for between 21% and 26% of patients with New
South Wales (NSW) treating over half of all patients with
IMRT. It would be interesting to determine factors
affecting this variation but the need for individual centre
anonymity precluded this for this study. The previous
iteration of this study reported a 19.6% use of IMRT.9
Table 4. Top 10 magnetic resonance imaging (MRI) fusion indications
and usage.
MRI fusion indications MRI fusion usage by site
Site n
Percentage
of total MRI Site n
Percentage
of each site
Prostate 107 39.92 Benign
tumours
13 68.42
Brain 66 24.62 Brain 66 37.29
Head and
neck
23 8.58 Whole
CNS
2 33.33
Rectum 18 6.72 Trachea 1 33.33
Benign
tumours
13 4.85 Endocrine
tumours
1 25.00
Soft-tissue
sarcoma
7 2.61 Prostate 107 24.37
Bladder 6 2.24 Soft-tissue
sarcoma
7 20.59
Skin SCC 5 1.87 Bladder 6 18.18
Breast 4 1.49 Rectum 18 17.48
Anus 3 1.12 Head and
neck
25 12.17
Table 5. Top 10 PET fusion indications and usage.
PET fusion indications PET fusion usage by site
Site n
Percentage
of total PET Site n
Percentage
of each site
Lung 77 31.03 Mesothelioma 2 100.00
Head and
neck
62 24.99 Oesophagus 24 45.28
Oesophagus 24 9.67 Ovary 2 40.00
Rectum 18 7.25 Lung 77 39.90
Brain 12 4.84 Anus 10 37.04
Anus 10 4.03 Trachea 1 33.33
Lymph
nodes
8 3.22 Head and
neck
62 32.29
Lymphoma 8 3.22 Middle ear 1 25.00
Cervix 5 2.02 Lymph nodes 8 23.53
Melanoma 3 1.21 Cervix 5 21.74
Table 6. Relative usage of imaging modalities.
Modality
Percentage of all
patients
Percentage of
images
Megavoltage
planar
36.2 41.61
Megavoltage CT 4.2 4.81
Kilovoltage planar 34.3 39.39
Kilovoltage CT 12 13.69
Ultrasound 0.4 0.5
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When compared to the current results for the national
(37%) and Queensland data (25.9%) it is clear that IMRT
use in Australia is increasing in prevalence. A comparison
with published data also confirms this trend in other
countries.3,11,13 It was noteworthy that of the 19 patients
treated for benign conditions 10 received resource-
intensive IMRT. It is likely that this result was influenced
by benign pituitary and meningioma treatments. It is
clear that IMRT usage in Australia is relatively high when
compared to published data and is steadily increasing.
Jacobs14 raises the interesting issue of increasing IMRT
incidence linked to Medicare funding, although anecdotal
evidence suggests that the cost-workload balance in
Australia makes it less likely to be a factor.
This strong utilisation of arc therapy technologies for
prostate and head and neck tumours is supported by the
literature and associated with improved outcomes for
these patients.15 While arc therapy was not delivered to
any of the six paediatric cases treated, half the cases were
treated with IMRT despite the decreased monitor unit
and treatment times offered by VMAT. This may be due
to concerns around dose baths and thereby potential
increased risk of secondary malignancies and growth
defects. It is also important to note that funding and
reimbursement challenges within the private sector may
have influenced VMAT implementation.
Patterns of image fusion use
The superior soft-tissue visualisation offered by MRI-CT
fusion significantly enhances localisation of intracranial,
head and neck16 and prostate tumours.17 This study’s data
indicated an overall increase in MRI-CT fusion use when
compared to the previous study’s 6.9%.9 The MRI data
from this study again highlighted the resource-intensive
nature of benign tumours with 13 of the 19 patient datasets
using the technique. Over the past decade, use of PET and
CT image fusion (PET-CT) has improved precision of
tumour volume delineation. In particular, this allows for a
reduction in margins and sparing of normal tissue with
potential-dose escalation for certain tumours. The
literature suggests that PET-CT image fusion is of
particular use in delineating lung cancers.18 The results
from this study demonstrate high uptake of PET-CT fusion
for lung patients and correlates well with existing
literature.19 Interestingly, when compared to data from the
previous study,9 where PET-CT fusion was used in 11.3%
of patients, it can be seen that there was an overall decrease
in its use. This may be influenced by different State
practices but the corresponding increase in the use of MRI-
CT fusion may go some way to explaining this.
State-wide variations indicated a slightly lower uptake
of MRI fusion for Queensland and Victoria and a
comparatively low uptake of PET fusion for South
Australia and Western Australian despite average numbers
of indicated patients being treated. To some extent, this
may be influenced by cyclotron availability with facilities
in place in Victoria, NSW, Western Australia and
Queensland. The evidence base19 also continues to
establish new roles and developing technology for PET. It
will be interesting to see if future iterations of this study
reveal how this evidence affects PET fusion data and
whether image fusion becomes an established method of
monitoring tumour regression during RT.
Image-guided radiotherapy
The data demonstrated increasing use of kV cone-beam
equipment with 12% of patients nationally receiving a
cone beam computed tomography (CBCT) image
compared to 8.5% last time; this is consistent with the
published data.20
When comparing the uptake in Queensland directly
between the two studies, there was a modest increase from
11.2% to 12% suggesting the findings may be skewed
slightly by increased usage in other States. Although too
small to be significant with this method, any increase may
reflect the reticence to add to the dose burden when
compared to kV planar imaging. IGRT for head and neck
cancer was well established across Queensland in 2012 and
this is repeated again Examination of Table 1 reveals that
NSW used CBCT for 17.3% of patients; most other States
were on a par at between 9% and 12%. Of the 321 CBCT
images taken on the census date 36% were prostate
patients, 16% head and neck and 13% lung. It will be
interesting to see how increasing use of adaptive RT
protocols influence use of CBCT in future iterations.
Fiducial markers were utilised in 53% of prostate
patients despite recommendations for their use in the
evidence base.21 With CBCT being indicated for patients
without fiducial markers with only 36% of prostate
patients receiving CBCT, it is unclear how some patients’
motion was accounted for. Further study in this area
would be of value.
There were some clear trends in how different
modalities were used. Most planar MV images were used
for verification of the breast, with bone, brain and lung
treatments also ahead of the image-reliant sites such as
the prostate and head and neck. The benefits of soft-
tissue definition associated with kV imaging are obviously
not as clear for these tumour sites. It was interesting to
see that of the 19 benign tumours treated there were 16
imaging incidences reported. It is not known how many
of these represented multiple imaging modalities for the
same patient, but reinforces the finding of benign
tumours being resource intensive.
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Limitations of the study
As with the previous study, there are some limitations
associated with the method. Although sufficient data
existed to determine trends on a national scale, the
participation rate was lower than expected. Some centres
did not employ a RT educator to collate the data, while
others had concerns about data sensitivity. Measures to
ameliorate the latter concern were taken but future data
collection may be enhanced by provision of a research
assistant to those centres struggling with staffing levels.
This would also allow random audit of data to check
robustness of data collection.
While the design of the study allows useful information
to be captured about the range and mix of patients and
treatment approaches, it provides limited insight as to
why individual centres adopt particular technologies or
modalities. A more wide-spread data collection technique
such as the National RT Dataset in the UK8 would help
determine factors influencing local decisions about
routine treatment approaches.
Recruitment issues aside, the study method also allows
for possible limitations with the random date possibly not
being representative. Responses could have been influenced
by timing in relation to regular clinics, oncologist availability
and resource availability. Such random fluctuations are
expected to decrease as sample size increases and future
wider participation may reveal the extent of this.
By far, the greatest limitation of the study relates to
data entry error with a large number of individuals
responsible for transcribing large quantities of data on
top of a busy workload. Reported single-entry errors are
in the region of 36 per 10,000 entries22; this can
potentially be reduced by using double data entry.
Transcription errors in this study were further
compounded by possible misinterpretation of guidelines.
Although guidelines were developed and validated in a
previous study, there was a definite discrepancy with
interpretation of imaging frequency reporting. These data
were discarded during the analysis phase and future
iterations will need more specific guidance.
As with the previous study, the proforma utilised a
simplified system of data classification for ease of
interpretation, speed of entry and reporting purposes.
While this is valuable for broad trend spotting, there is a
loss of accuracy with tumour pathologies and stages and
inability to perform correlation analysis for individual
patients.
Implications of the study
The results of the study in general confirm the validity of
the research method when compared with those from the
previous study. The method is a relatively convenient and
powerful means of monitoring radiotherapy treatment
and technology uptake trends. The overall trend
demonstrated by the two studies is that of increasing use
of technology in RT; in particular there is increasing use
of imaging technology as part of the standard workload
in line with recommendations for IGRT use from the
USA23 and the UK.24 From an educational perspective
these findings support increased emphasis on IGRT at
both pre- and post-registration provision.
The authors are particularly interested in using the data
to inform curriculum development of academic programs
in Australia and to ensure training is matched to current
workforce patterns of practice.25 With the implementation
of new technologies in radiotherapy comes the challenge to
keep up to date with teaching content. What is common
practice in one State may not be reflective of national
trends and best practice. A regular audit such as this study
provides a broader national perspective of practice and
techniques. The results allow mapping of content to reflect
current practice and respond to trends in new techniques
for future review. Examples from this are the broad
increased use of IGRT nationally and the specific increase
in IMRT for prostate cases in particular; these results have
led to earlier and more intensive teaching in IMRT. In
considering the future formation of a national competency
development framework for RT students, the results of this
audit form a valuable component.
An interesting finding from this data analysis has been
the apparent resource-intensive nature of benign tumour
radiotherapy. For a traditionally small component of the
radiotherapy workload, there is a high uptake of IMRT,
fusion and IGRT; some of these technologies contribute
an increased dose to these patients. It may be cogent to
further examine the extent to which benign tumours
utilise resources compared with malignancies.
Another point to consider is whether differences in
uptake of technology between States are indicative of
different policy implementation and resource availability
or a by-product of the random audit method used. There
has been much discussion related to the post-code lottery
of cancer treatment26,27 with variability between and
across different countries; these data could suggest that
this also applies to more wide-spread differences.
Certainly within Australia, newer technology is established
in some States more than others with both geographical
and political factors impacting on their availability.
Conclusions
Findings from this study indicate the increasing use of
emerging IMRT, image fusion and IGRT technology in
Australian RT planning and delivery phases. This must be
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reflected in national RT curriculum development with
increased provision of theoretical teaching and practical
experience with these technologies. The results also
highlight the resource-intensive nature of planning and
treating benign tumours; frequently requiring additional
radiation dose. The single-day census method offers a
relatively convenient means of measuring and tracking
RT resources. In the absence of more formal national
data collection procedures, wider use of this tool has the
potential to not only track trends in technology
implementation but also inform evidence-based guidelines
for referral and resource planning.27,28
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This article presents the results of a national snapshot survey of radiation therapy practice in Australia. Results include
prevalence of treated tumour sites and use of a range of technology.
